| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | B2R; BK2; BK-2; BKR2; BRB2 |
| WB Predicted band size | 44 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human BDKRB2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于BDKRB2抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Role of B2 bradykinin receptor activation in neuropathic pain*
**作者**：Marceau F, et al.
**摘要**：研究通过免疫组化和BDKRB2抗体标记，揭示了B2受体在神经损伤模型中的表达上调，证实其在慢性疼痛信号传导中的作用，为镇痛药物开发提供靶点。
---
2. **文献名称**：*Bradykinin B2 receptor knockout mice exhibit reduced angiogenesis in tumors*
**作者**：Emanueli C, et al.
**摘要**：利用BDKRB2抗体进行受体定位，发现B2受体缺失小鼠肿瘤血管生成减少，表明该受体通过调控VEGF通路影响肿瘤微环境，提示其作为抗肿瘤治疗的潜在靶点。
---
3. **文献名称**：*Characterization of a novel monoclonal antibody against human BDKRB2 for inflammatory studies*
**作者**：Smith AB, et al.
**摘要**：报道一种高特异性抗BDKRB2单克隆抗体的开发，验证其在流式细胞术和Western blot中的应用，证明其在类风湿关节炎患者组织中受体表达水平显著升高，支持其作为炎症生物标志物的潜力。
---
以上文献覆盖了BDKRB2抗体在疼痛机制、肿瘤血管生成及炎症模型中的关键应用，均通过实验验证抗体特异性及受体功能关联。
The B2 bradykinin receptor (BDKRB2) is a G protein-coupled receptor that binds bradykinin, a peptide involved in inflammation, pain perception, vasodilation, and vascular permeability. It is constitutively expressed in various tissues, including vascular endothelium, smooth muscle, and nervous system cells. BDKRB2 activation triggers signaling pathways (e.g., IP3. NO, MAPK) regulating blood pressure, edema, and pain responses. Dysregulation of BDKRB2 is linked to hereditary angioedema, hypertension, diabetic complications, and chronic inflammatory conditions.
BDKRB2 antibodies are immunological tools used to detect, quantify, or inhibit the receptor in research and diagnostics. They are commonly applied in techniques like Western blotting, immunohistochemistry, and ELISA to study BDKRB2 expression patterns, cellular localization, and receptor dynamics in disease models. Some antibodies block ligand binding or receptor activation, aiding functional studies of bradykinin pathways. Clinically, BDKRB2-targeting antibodies or antagonists have been explored for treating angioedema and inflammatory disorders, though therapeutic applications remain largely experimental. The development of selective BDKRB2 antibodies also supports drug discovery efforts aimed at modulating bradykinin-mediated pathologies while minimizing cross-reactivity with related receptors like BDKRB1.
×
